NeuroOne Medical Technologies Corp.

As of December 22, 2022, NeuroOne Medical Technologies Corp. is considered a risky investment due to its high price-to-book ratio of 25.74, negative EV to EBITDA of -4.39, and extremely low return on equity of -626.73%, indicating poor financial health and underperformance compared to the S&P 500.

As of December 22, 2022, NeuroOne Medical Technologies Corp. is considered overvalued and risky due to its significant negative financial metrics, including a Price to Book Value of 25.74 and a dangerously low ROE of -626.73%.

As of June 17, 2025, the market trend is mildly bearish, influenced by daily moving averages and weekly KST, despite some mildly bullish signals from the MACD and Dow Theory, leading to overall uncertainty.

NeuroOne Medical Technologies Corp. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $1 million and a net loss of $2 million as of March 2025, with a market cap of $32.38 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -626.73%.

As of Jun 18, NeuroOne Medical Technologies Corp. has a market capitalization of 32.38 million, with net sales of 8.76 million and a net profit loss of 6.60 million over the latest four quarters. Shareholder's funds are 0.82 million, and total assets amount to 5.37 million as of Sep 24.